zenasbio.com (ZBIO) Market Value to Book Value Ratio
Zenas Biopharma Inc (ZBIO) focuses on developing treatments for rare systemic inflammatory diseases, leveraging the success of obexelimab and its collaboration with BMS. The business operates in a stable environment devoid of political risks, and the indicator stands at 7.40. Historical price action clearly demonstrates market expectations for the company, which is developing unique CD19 antibodies to achieve sustained recovery for patients with severe autoimmune pathologies.
Zenas Bio (ZBIO) - metric breakdowns and financial figures
- market value and analyst target forecast:
- market capitalization details:
- book capitalization data:
- debt obligations and liquidity statistics:
Debt to Equity Zenas Biopharma Inc|ZBIO - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Zenas Biopharma, Inc.|ZBIO - Company Total Debt|Debts to Book Capitalization Zenas Biopharma, Inc.|ZBIO - Company Long-Term Debts|Company Current Liabilities Zenas Biopharma|Quick Ratio zenasbio.com
- earnings and valuation multiples indicators:
Basic company analysis:Zenas Biopharma Inc - ZBIO
This ratio reflects the gap between the market value of assets and their book value, measuring the level of investor confidence in the business's future potential. When analyzing the price-to-book history, it should be noted that for Zenas Biopharma Inc (ZBIO), the high premium is driven by clinical trial expectations, as actual pricing power will only emerge following government patent approval.
Competitor analysis
argenx SE (ARGX) - Market Value to Book Value Ratio|Market-to-Book Ratio biontech.de (BNTX)|Market Value to Book Value Ratio abivax.com|ADMA Biologics Inc - Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio PTGX|IMVT (Immunovant Therapeutics) - Market Value to Book Value|Market Capitalization to Book Value Ratio KNSA (Kiniksa Pharmaceuticals)|Market Capitalization to Book Value Ratio grifols.com GRFS|ADPT - Market Value to Book Value Ratio|Market Value to Book Value CLDX (Celldex Therapeutics Inc)|Aurinia Pharma (AUPH) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio BioCryst Corp|VERA (Vera Therapeutics, Inc.) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio dianthustx.com|Market Cap to Net Assets Ratio PHVS (Pharvaris)|ABCL (AbCellera Biologics) - Market Value to Book Value|Market Capitalization to Book Value Ratio TRML (Tourmaline Corp)|Market Capitalization to Book Value Precigen Corp (PGEN)|PHAR - Market Value to Book Value Ratio|nektar.com (NKTR) - Market Cap to Net Assets Ratio|Upstream Bio (UPB) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio Immunome Inc|Market Cap to Net Assets Ratio GOSS|Market Capitalization to Book Value Ratio KalVista Corp|Market Value to Book Value Ratio Septerna Inc (SEPN)|pieris.com - Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio SVRA (Savara)|Rigel Pharma (RIGL) - Market-to-Book Ratio|ANAB: Market Cap to Net Assets Ratio|Market Capitalization to Net Assets ATXS|ENGN: Market Capitalization to Book Value Ratio|Market-to-Book Ratio rapt.com (RAPT)|Market Value to Book Value Ratio Aerovate Therapeutics, Inc.|Capitalization to Book Value Ratio ACRS (Aclaris Therapeutics Inc.)|Market Capitalization to Book Value Ratio KYTX|Market Capitalization to Book Value Ratio Tiziana Life Sciences, Ltd. (TLSA)|Market Value to Book Value Ratio Cabaletta Bio, Inc. CABA|Market Capitalization to Book Value ventyxbio.com (VTYX)|THTX: Market Cap to Net Assets Ratio|Market Value to Book Value AVTX (Avalo Therapeutics, Inc.)|ELDN: Market Capitalization to Book Value Ratio|AGEN (Agenus, Inc) - Market Value to Book Value Ratio|CLYM (Climb Bio Inc) - Market Capitalization to Book Value Ratio|zurabio.com (ZURA) - Market Capitalization to Book Value|Market Value to Book Value Ratio aTyr Pharma (ATYR)|ADAG - Market-to-Book Ratio|Market Value to Book Value Ratio Ikena Oncology IMA|STTK (Shattuck Labs Inc) - Market Capitalization to Net Assets|Equillium Bio - Market Capitalization to Book Value Ratio|Market Value to Book Value CNTB (Connect Biopharma)|IMUX: Market Capitalization to Book Value Ratio|Atara Bio (ATRA) - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio InflaRx NV|XFOR: Market Value to Book Value|Market Value to Book Value Ratio Adicet Bio (ACET)|Market Cap to Net Assets Ratio celularity.com CELU|Market Capitalization to Book Value Ratio INMB (INmune Bio)|Market Capitalization to Book Value Ratio Barinthus Biotherapeutics PLC BRNS|KZR: Market Cap to Net Assets Ratio|Market Value to Book Value SABS (SAB Biotherapeutics Inc)|AKTX: Market Capitalization to Book Value Ratio|ENLV - Market Capitalization to Book Value|Market Value to Book Value Ratio Q32 Bio Inc|Capitalization to Book Value Ratio GOVX (GeoVax Labs)|Market Capitalization to Book Value Ratio EDSA|Market Cap to Net Assets Ratio iBio Corporation IBIO|Carisma Therapeutics Inc. - Market Cap to Net Assets Ratio|XTLB (xtlbio.com) - Market Capitalization to Net Assets|Bolt Bio - Market Capitalization to Book Value Ratio|HCWB: Market Value to Book Value Ratio|APVO: Market Capitalization to Book Value Ratio|AIM - Market Capitalization to Book Value|Market Value to Book Value Ratio Aditxt Inc.|Market-to-Book Ratio gribio.com GRI|Market Value to Book Value Ratio XORTX Therapeutics (XRTX)|HIND: Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio REVB (Revelation Bio)|Market Value to Book Value INDP|Scinai Immunotherapeutics - Market Capitalization to Book Value Ratio|CALI - Market Capitalization to Book Value Ratio|affimed.com (AFMD) - Market Value to Book Value Ratio|Allakos - Market Value to Book Value|Market Value to Book Value Ratio HOOKIPA Pharma, Inc.|Market Cap to Net Assets Ratio IGM Bio (IGMS)|Market Capitalization to Book Value Ratio ITOS|Market Capitalization to Book Value Ratio oceanbiomedical.com (OCEA)|TC BioPharm - Market Cap to Net Assets Ratio|Market Value to Book Value THRD